(ny-LOH-tih-nib)
This page contains brief information about nilotinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Nilotinib is approved to treat:
- Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used:
- In adults and children aged 1 year or older with newly diagnosed chronic phase CML.
- In adults with chronic phase or accelerated phase CML that cannot be treated with or that did not respond to treatment that included imatinib mesylate.
- In children aged 1 year or older with chronic phase CML that cannot be treated with or that did not respond to tyrosine kinase inhibitor therapy.
Nilotinib is also being studied in the treatment of other types of cancer.
More About Nilotinib
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Nilotinib – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Nilotinib Hydrochloride Monohydrate – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
